Neuroimmunologic aspects of psoriasis.
Raychaudhuri
S P
SP
Psoriasis Research Institute, Palo Alto, California 94301, USA.
Farber
E M
EM
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001706:Biopsy; D001713:Biphenyl Compounds / Q000627:therapeutic use; D006801:Humans; D007150:Immunohistochemistry; D007249:Inflammation / Q000473:pathology; D015552:Injections, Intralesional; D020932:Nerve Growth Factor / Q000502:physiology; D015213:Neuroimmunomodulation; D009479:Neuropeptides / Q000502:physiology; D015717:Peptide T / Q000008:administration & dosage; D011565:Psoriasis / Q000209:etiology* / Q000503:physiopathology / Q000523:psychology / Q000628:therapy; D011598:Psychoneuroimmunology; D017475:Receptors, Nerve Growth Factor / Q000502:physiology; D012064:Relaxation Therapy; D012867:Skin / Q000294:innervation / Q000473:pathology; D013315:Stress, Psychological / Q000150:complications; D013373:Substance P / Q000037:antagonists & inhibitors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001713:Biphenyl Compounds; D009479:Neuropeptides; D017475:Receptors, Nerve Growth Factor; D015717:Peptide T; D013373:Substance P; D020932:Nerve Growth Factor; C066892:CP 96345